RTS,S/AS01 malaria vaccine and child mortality

Affiliations

¹ Institute of Public Health, Medical School, Ruprecht-Karls-University, 69124 Heidelberg, Germany. Electronic address: olaf.mueller@urz.uni-heidelberg.de.
² Department of Public Health, New York University, New York, NY, USA.
³ Institute of Medical Biometry and Epidemiology, University of Hamburg, Medical School, Hamburg, Germany.

Comment

Olaf Müller et al. Lancet. 2015.

. 2015 Oct 31;386(10005):1736.

doi: 10.1016/S0140-6736(15)00694-7.

¹ Institute of Public Health, Medical School, Ruprecht-Karls-University, 69124 Heidelberg, Germany. Electronic address: olaf.mueller@urz.uni-heidelberg.de.
² Department of Public Health, New York University, New York, NY, USA.
³ Institute of Medical Biometry and Epidemiology, University of Hamburg, Medical School, Hamburg, Germany.

No abstract available

Comment on

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.
RTS,S Clinical Trials Partnership. RTS,S Clinical Trials Partnership. Lancet. 2015 Jul 4;386(9988):31-45. doi: 10.1016/S0140-6736(15)60721-8. Epub 2015 Apr 23. Lancet. 2015. PMID: 25913272 Free PMC article. Clinical Trial.
Vaccines: a step change in malaria prevention?
[No authors listed] [No authors listed] Lancet. 2015 Apr 25;385(9978):1591. doi: 10.1016/S0140-6736(15)60774-7. Lancet. 2015. PMID: 25943796 No abstract available.